Teoxane data points to demand for volume restoration after weight loss

Teoxane has released survey data on patient attitudes to facial fat loss following weight loss, pointing to a treatment gap that the hyaluronic acid brand argues favours volume-restoration work over conventional line and wrinkle correction. The findings come as GLP-1 medication and rapid weight loss push changes in facial contour up the list of patient concerns.

The research was carried out by Norstat on behalf of Teoxane among 2,500 UK participants, with data gathered in August 2025 and released this year. It found that 65 per cent of women are worried about facial fat loss in the future, a concern the brand links to the growing visibility of rapid weight loss and its effect on the face.

Among respondents, 42 per cent reported experiencing rapid weight loss. Within that group, the cause was diet and exercise for 61 per cent, a medical reason for 29 per cent, and GLP-1 medication such as Ozempic, Wegovy or Mounjaro for 10 per cent. Of those who lost weight rapidly, 60 per cent felt they had experienced noticeable facial fat loss, or what is popularly termed "Ozempic face". The most commonly noticed changes were a more prominent bone structure, cited by 37 per cent, and loss of temple volume, cited by 31 per cent.

The data also suggests a mismatch between the changes patients notice and the treatments they pursue. Asked what they had sought or would seek treatment for after weight loss, respondents most often named reducing fine lines and wrinkles (39 per cent) and improving sagging skin (36 per cent), rather than restoring lost volume. Teoxane positions this as an opportunity for practitioners to educate patients on temple filler and on hyaluronic acid volume restoration to soften contours and counter the hollowing that can follow fat loss, a market the brand expects to grow.

Dr Sabrina Shah-Desai of Perfect Eyes said facial fat loss has become one of the most common conversations in aesthetic medicine. "Patients are increasingly aware that changes in facial shape, contour and support can make them look tired or older, even when they've improved their overall health through weight loss," she said. "We're seeing concerns about facial fat loss across all age groups, not just in traditional ageing patients."

Dr Raul Cetto of Le Petit Saint said the topic now comes up frequently in clinic. “It’s now one of the most frequent topics I encounter in clinic, and the data backs that up. In the UK alone, an estimated 1.6 million adults used GLP-1 weight loss medications between early 2024 and early 2025 – and around 3.3 million more have said they’d like to try them in 2026. But this isn’t only a weight loss medication story. Patients across the board are becoming far more informed about natural facial ageing too. They’re no longer simply asking about lines and wrinkles – they’re asking why their face looks ‘tired’ or ‘deflated’, and they want to understand why. That shift in awareness represents a real opportunity for us as practitioners to have better, more honest conversations and deliver more meaningful outcomes.”

Teoxane is a Swiss laboratory founded in 2003 and based in Geneva, known for its TEOSYAL and RHA resilient hyaluronic acid dermal filler ranges.